In a mouse model of non-alcoholic steatohepatitis (NASH), SR9009 was reported to reduce glucose levels, improve glucose tolerance, and inhibit the expression of fibrotic markers, such as collagen α1(III) (COLl3A1), α-SMA, STAT1, MMP13, TIMP1, and TGF-β. Here, STAT1 is linked to metabolic dysfunction-associated steatohepatitis.